Market Overview

Takeda Recognizes ALK+ Day with Launch of tALK+ Initiative During November's Lung Cancer Awareness Month

Share:

− tALK+ Promotes the Insights, Contributions and Individuals Making a
Positive Impact on the Forefronts of ALK+ Non-Small Cell Lung Cancer
(NSCLC) −

− Launch of ALKConnect Registry Connects and Informs Patients Living
with ALK+ NSCLC −

In recognition of this year's Lung Cancer Awareness Month and in
conjunction with the second annual ALK+ Day, Takeda Pharmaceutical
Company Limited (TSE:4502)
today announced the launch of tALK+ (Talk Positive), an
initiative that highlights positive experiences and stories from the
non-small cell lung cancer (NSCLC) community and educates others about
anaplastic lymphoma kinase-positive (ALK+) NSCLC, a type of lung cancer
impacting approximately two to eight percent of NSCLC patients.1
Throughout the month and on ALK+ Day, November 13, Takeda will recognize
on social media the important strides being made by the NSCLC community,
and encourage patients and their families, doctors and researchers to
get involved in the tALK+ conversation by:

This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171108005855/en/

  • Following @TakedaOncology on Facebook,
    Twitter
    and Instagram
    and sharing positive insights and personal stories of those impacted
    by ALK+ NSCLC to recognize the significant moments and/or people who
    have made a positive impact in their lives using the social media
    hashtag #tALKpositiveNSCLC.
  • Visiting LivingwithALK.com/tALKpositive
    to learn facts about ALK+ NSCLC and the people it affects.

For the month of November, every time the hashtag is used, Takeda will
make a donation to the Bonnie
J. Addario Lung Cancer Foundation
to advance lung cancer awareness
and treatment.

"Through tALK+, our hope is to spark positive, supportive dialogue
across the ALK+ NSCLC community that drives education around the
differences inherent in this rare form of lung cancer and recognizes the
researchers, advocates, patients and loved ones touched by this
disease," said Bonnie J. Addario, Founder, Chair & Lung Cancer Survivor,
Bonnie J. Addario Lung Cancer Foundation. "We're proud to join Takeda in
raising awareness about ALK+ NSCLC and demonstrating our support for
patients and families."

In observance of ALK+ Day, Takeda will be hosting a live webinar
entitled Overview of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) on
November 13 at 12:00 p.m. ET and 4:30 p.m. ET. During these live
educational events, H. Jack West, MD and Mark Socinski, MD, will review
a broad spectrum of topics across the ALK+ NSCLC disease state. To
register for one of the webinars, please visit: http://idmeetings.com/OncologyWebcast.

"I look forward to joining Takeda in raising awareness about ALK+ NSCLC
and participating in the upcoming live educational webinar events this
ALK+ Day," said H. Jack West, MD, Medical Director, Thoracic Oncology
Program, Swedish Cancer Institute. "For Lung Cancer Awareness Month and
beyond, it is important to advance education and understanding of this
rare form of cancer, as well as to engage patients to become active
participants in the management of their disease."

This month, Takeda is also launching the ALKConnect Registry, a
patient-focused registry that collects information and insights directly
from patients living with ALK+ NSCLC to better understand their
experiences living with the disease. On the platform, patients have the
opportunity to participate in surveys to share experiences, access data
and insights from other registry participants, and learn about new
research studies in the ALK+ NSCLC space. For more information, please
visit ALKConnect.com.

About ALK+ NSCLC

Non-small cell lung cancer (NSCLC) is the most common form of lung
cancer, accounting for approximately 85 percent of the estimated 222,500
new cases of lung cancer diagnosed each year in the United States,
according to the American Cancer Society. Genetic studies indicate that
chromosomal rearrangements in anaplastic lymphoma kinase (ALK) are key
drivers in a subset of NSCLC patients. Approximately two to eight
percent of patients with metastatic NSCLC have a rearrangement in the
ALK gene.

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and central nervous system therapeutic areas plus
vaccines. Takeda conducts R&D both internally and with partners to stay
at the leading edge of innovation. New innovative products, especially
in oncology and gastroenterology, as well as our presence in Emerging
Markets, fuel the growth of Takeda. More than 30,000 Takeda employees
are committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its corporate
website, www.takeda.com,
and additional information about Takeda Oncology, the brand for the
global oncology business unit of Takeda Pharmaceutical Company Limited,
is available through its website, www.takedaoncology.com.

1 Guérin A, et al. J Med Econ, 2015;18(4):312-322.

View Comments and Join the Discussion!
 

Partner Center